AZD0120: Dual-Targeting CAR-T Therapy Shows Promise in Preclinical Multiple Myeloma Studies
Researchers have developed AZD0120, a dual-targeting BCMA/CD19 CAR-T cell therapy for multiple myeloma that uses a rapid manufacturing process called FasTCAR. The therapy employs a novel "loop" CAR design combining a humanized anti-BCMA antibody fragment with an anti-CD19 fragment, and demonstrated superior tumor control and CAR-T cell expansion compared to conventionally manufactured versions in animal models. The findings support moving AZD0120 into clinical trials, with the potential to improve both treatment outcomes and patient access by shortening manufacturing timelines.
AZD0120 is a dual-targeting chimeric antigen receptor (CAR)-T cell therapy designed to simultaneously target BCMA and CD19, two proteins relevant to multiple myeloma (MM). The therapy uses a novel "loop" CAR architecture incorporating a humanized anti-BCMA single-chain variable fragment (clone SG) and an FMC63-derived anti-CD19 fragment, both of which retained functional antigen binding. Conventionally manufactured AZD0120 (AZD0120C) showed minimal tonic signaling, limited response to soluble BCMA, and preservation of less-differentiated immune cell phenotypes, while still producing robust cytokine responses upon engaging BCMA-positive tumor cells. In vitro, AZD0120C performed comparably to benchmark BCMA CAR-T therapies, and in animal xenograft models it demonstrated strong expansion and tumor control. The FasTCAR manufacturing process — which shortens the time from patient blood draw to infusion and enriches for less-differentiated T cell phenotypes — further improved performance: AZD0120 outperformed AZD0120C in tumor control and CAR-T expansion across multiple disseminated cancer models, including MM.1S, NALM-6, and JeKo-1, even at lower cell doses. The authors conclude that these preclinical data support clinical evaluation of AZD0120 as a potentially differentiated treatment option that could also improve patient access by reducing manufacturing complexity.
What's missing
The study is entirely preclinical; no human clinical trial data exist yet for AZD0120. Key limitations include the use of immunodeficient xenograft mouse models, which may not fully replicate human immune responses or the tumor microenvironment in MM patients. The study does not address potential toxicities such as cytokine release syndrome or neurotoxicity in humans, nor does it compare AZD0120 directly to approved therapies like idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) in head-to-head models. The durability of responses and the clinical relevance of the FasTCAR phenotypic advantages remain to be established in human trials.
What different sources said
- bioRxivCenter
BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myeloma
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.